Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

News SummaryMost relevantAll newsSector newsTweets 

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

share with twitter share with LinkedIn share with facebook
share via e-mail
04/26/2012 | 07:01pm CET
   By Peter Loftus 

Drug maker Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas.

Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries."

The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing.

Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA.

U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement.

Last year, Johnson & Johnson (>> Johnson & Johnson) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein.

Other drug makers--including Pfizer Inc. (>> Pfizer Inc.), Merck & Co. (>> Merck & Co., Inc.) and Eli Lilly & Co. (>> Eli Lilly & Co.)--also have been the subjects of federal inquiries regarding the FCPA.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
03/24 BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion Recommending Opdivo (nivol..
03/23 BRISTOL-MYERS SQUIBB COMPANY (OTCMKT : BMYMP) Files An 8-K Departure of Director..
03/23 BRISTOL MYERS SQUIBB CO : Change in Directors or Principal Officers (form 8-K)
03/23 FINDINGS FROM BRISTOL-MYERS SQUIBB C : An HCV Protease Inhibitor With Preferenti..
03/23 BRISTOL MYERS SQUIBB : Patent Issued for Crystalline Forms of N,N-Dicyclopropyl-..
03/23 BRISTOL MYERS SQUIBB : Patent Issued for Crystalline Form of N,N-Dicyclopropyl-4..
03/23 BRISTOL MYERS SQUIBB : Patent Issued for Sensitive Method to Analyse Free PEG-Ma..
03/23 BRISTOL MYERS SQUIBB : to Announce Results for First Quarter 2017 on April 27
03/22 BRISTOL MYERS SQUIBB : CytomX pen expanded $3.6B biobucks research deal
03/20 BRISTOL MYERS SQUIBB : and CytomX Therapeutics Extend Worldwide Collaboration to..
More news
Sector news : Pharmaceuticals - NEC
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/24 European advisory committee backs Bristol-Myers' Opdivo for head and neck can..
03/23 Bristol Failure Makes Small Dent In CXCR4-Blocking Approach
03/23 Pharma Development Budgets Grow As Roche Remains A Believer
03/21 Biotechs under pressure after Trump (again) decries high drug prices
03/21 Selling Or Trimming Reasons Within My 86 Stock Portfolio
Financials ($)
Sales 2017 19 706 M
EBIT 2017 5 203 M
Net income 2017 4 660 M
Finance 2017 232 M
Yield 2017 2,91%
P/E ratio 2017 20,19
P/E ratio 2018 18,51
EV / Sales 2017 4,66x
EV / Sales 2018 4,45x
Capitalization 92 079 M
More Financials
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 55,3 $
Spread / Average Target -1,1%
Consensus details
EPS Revisions
More Estimates Revisions
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.60%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
More Results